Inhibrx Biosciences (INBX) EBITDA (2023 - 2025)
Inhibrx Biosciences' (INBX) quarterly EBITDA came in at -$30.9 million in Q4 2025, up 38.06% year-on-year from -$22.4 million in Q4 2024, and up 8.54% on a QoQ basis from -$33.8 million in Q3 2025.
Inhibrx Biosciences (INBX) EBITDA (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of EBITDA data on file, last reported at -$30.9 million in Q4 2025.
- On a quarterly basis, EBITDA rose 38.06% year-over-year to -$30.9 million in Q4 2025; TTM through Dec 2025 was -$135.0 million, a 59.26% increase from a year earlier, with the FY2025 full-year figure at -$135.0 million, up 59.26% from the prior year.
- EBITDA for Q4 2025 stood at -$30.9 million, up from -$33.8 million in the prior quarter.
- Over the last five years, EBITDA for INBX reached as high as -$27.4 million in Q2 2025 and fell as low as -$160.9 million in Q2 2024.
- Historically, EBITDA has averaged -$58.4 million across 3 years, with a median of -$45.8 million in 2023.
- Across the five-year window, EBITDA slumped 289.22% in 2024 and surged 82.98% in 2025, its largest moves.
- Year by year, EBITDA stood at -$88.3 million in 2023, then soared by 43.45% to -$49.9 million in 2024, then jumped by 38.06% to -$30.9 million in 2025.
- Per Business Quant data, the three most recent EBITDA figures were -$30.9 million in Q4 2025, -$33.8 million in Q3 2025, and -$27.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - | -30.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -30.92 Mn |
| Sep 30, 2025 | -33.81 Mn |
| Jun 30, 2025 | -27.39 Mn |
| Mar 31, 2025 | -42.90 Mn |
| Dec 31, 2024 | -49.93 Mn |
| Sep 30, 2024 | -46.80 Mn |
| Jun 30, 2024 | -160.90 Mn |
| Mar 31, 2024 | -73.83 Mn |
| Dec 31, 2023 | -88.29 Mn |
| Sep 30, 2023 | -45.83 Mn |
| Jun 30, 2023 | -41.34 Mn |